European consensus for the diagnosis of MCI and mild dementia: Preparatory phase

Abstract

Introduction Etiological diagnosis of neurocognitive disorders of middle‐old age relies on biomarkers, although evidence for their rational use is incomplete. A European task force is defining a diagnostic workflow where expert experience fills evidence gaps for biomarker validity and prioritization. We report methodology and preliminary results. Methods Using a Delphi consensus method supported by a systematic literature review, 22 delegates from 11 relevant scientific societies defined workflow assumptions. Results We extracted diagnostic accuracy figures from literature on the use of biomarkers in the diagnosis of main forms of neurocognitive disorders. Supported by this evidence, panelists defined clinical setting (specialist outpatient service), application stage (MCI‐mild dementia), and detailed pre‐assessment screening (clinical‐neuropsychological evaluations, brain imaging, and blood tests). Discussion The Delphi consensus on these assumptions set the stage for the development of the first pan‐European workflow for biomarkers’ use in the etiological diagnosis of middle‐old age neurocognitive disorders at MCI‐mild dementia stages. Highlights Rational use of biomarkers in neurocognitive disorders lacks consensus in Europe. A consensus of experts will define a workflow for the rational use of biomarkers. The diagnostic workflow will be patient‐centered and based on clinical presentation. The workflow will be updated as new evidence accrues.

Superfluous, controversial and luxury issues in nuclear medicine

“…In this regard, the "European consensus for etiological diagnosis of neurocognitive disorders" has involved all the competent European scientific societies, including the European Association of Nuclear Medicine [2]. This initiative further supported the present role of our tools to support the differential diagnosis, especially in complex clinical scenarios such as the spectrum of frontotemporal degeneration and atypical parkinsonian syndromes.…”

Attitudes of Neurologists Toward the Use of Biomarkers in the Diagnosis of Early Alzheimer’s Disease

“…Biomarkers have changed the landscape of AD diagnosis in the decade [ 4, 5 ]. Eleven European scientific societies and Alzheimer Europe are working on the design of a workflow for biomarker-based etiological diagnosis in patients with MCI and mild AD dementia through literature review and Delphi methodology [ 23 ]. In a first round, the participants agreed that patients with mild cognitive or behavioral complaints should receive an accurate etiological diagnosis.…”

Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation

“…Previous reports also suggest the value of BBBM testing in specialized memory clinic settings to distinguish AD from other types of dementia, although challenges remain including clinical use of biomarkers in patients without objective cognitive impairment. [25][26][27]44 The current report adds to the weight of evidence to support the use of a BBBM test to diagnose amyloid pathology and offers some suggestions for its implementation.…”